Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The big pharma companies Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Ozempic: Weight-Loss Drug's Benefits And Risks Revealed in New Study
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.
The Health Risks and Benefits of Weight-Loss Drugs
The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,
Ozempic-style drugs tied to more than 60 health benefits and risks in biggest study-of-its-kind
Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.
Weight-loss drugs linked to benefits beyond dropping pounds
A new study published in the Nature Medicine monthly journal highlights the benefits and risks of weight-loss drugs like Ozempic and Wegovy. Positives include reduced risks of infections and cardiac arrest,
Weight-Loss Drugs Like Ozempic Linked To Lower Risk Of 42 Conditions
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.
Ozempic-type drugs could have benefits beyond treating diabetes
There's new evidence the class of drugs that includes Ozempic may have health benefits that go beyond diabetes treatment and weight loss. A major new study suggests these drugs could help with dozens of conditions ranging from Alzheimer's disease to drug addiction.
GlobalData on MSN2d
Novo Nordisk’s high-dose Wegovy increases weight loss and remains safe
Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.
BioSpace5d
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Is Novo Nordisk Stock a Buy?
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
The Financial Express3d
Weight loss pills Ozempic, Wegovy and Trizepatide enter Indian market
Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...
Massive new study finds drugs like Ozempic affect 175 conditions — including a few surprises
A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — ...
LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...